A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma

British Journal of Cancer

Volumn 111, Issue 12, 2014, Pages 2254-2261

  Lewin, J ^a   Khamly, K K ^a   Young, R J ^a   Mitchell, C ^a   Hicks, R J ^a,b   Toner, G C ^a,b   Ngan, S Y K ^a   Chander, S ^a   Powell, G J ^a,b,c   Herschtal, A ^a   Te Marvelde, L ^a   Desai, J ^a   Choong, P F M ^a,b,c   Stacker, S A ^a,b   Achen, M G ^a,b   Ferris, N ^a   Fox, S ^a   Slavin, J ^b   Thomas, D M ^a,b,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

FAZA; hypoxia; sarcoma; soft tissue sarcoma; sunitinib

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AZOMYCIN ARABINOSIDE F 18; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; SUNITINIB; TRACER; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTIANGIOGENIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CELL HYPOXIA; CELL METABOLISM; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPONATREMIA; LEUKOCYTE COUNT; LIMB PAIN; LIVER FAILURE; LYMPHEDEMA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DERMATITIS; RADIATION INJURY; RADIOSENSITIVITY; RASH; SIDE EFFECT; SKIN FIBROSIS; SKIN INFECTION; SOFT TISSUE SARCOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; TOXIC HEPATITIS; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR HYPOXIA; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; FEMALE; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; RADIATION RESPONSE; SARCOMA; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PYRROLES; RADIOTHERAPY, ADJUVANT; SARCOMA;

EID: 84927568819     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.537     Document Type: Article

References (50)

1. Achen MG, Williams RA, Minekus MP, Thornton GE, Stenvers K, Rogers PA, Lederman F, Roufail S, Stacker SA (2001) Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J Pathol 193(2): 147-154.
2. Brizel DM, Rosner GL, Harrelson J, Prosnitz LR, Dewhirst MW (1994) Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 30(3): 635-642.
3. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW (1997) Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38(2): 285-289.
4. Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69(3): 4-10.
5. Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B (2001) Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol 8(3): 260-267.
6. Cuneo KC, Geng L, Fu A, Orton D, Hallahan DE, Chakravarthy AB (2008) SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys 71(3): 873-879.
7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3): 232-239.
8. Evans SM, Hahn SM, Magarelli DP, Zhang PJ, Jenkins WT, Fraker DL, Hsi RA, McKenna WG, Koch CJ (2001) Hypoxia in human intraperitoneal and extremity sarcomas. Int J Radiat Oncol Biol Phys 49(2): 587-596.
9. Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77(7): 527-543.
10. Ferrara N, Gerber H-P, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6): 669-676.
11. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16(9): 4604-4613.
12. Francis P, Namlos HM, Muller C, Eden P, Fernebro J, Berner JM, Bjerkehagen B, Akerman M, Bendahl PO, Isinger A, Rydholm A, Myklebost O, Nilbert M (2007) Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 8: 73.
13. Gaustad J-V, Simonsen TG, Leinaas MN, Rofstad EK (2012) Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts. BMC Cancer 12(1): 388.
14. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML (2009) Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 27(19): 3154-3160.
15. Graeven U, Andre N, Achilles E, Zornig C, Schmiegel W (1999) Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J Cancer Res Clin Oncol 125(10): 577-581.
16. Groshar D, McEwan AJ, Parliament MB, Urtasun RC, Golberg LE, Hoskinson M, Mercer JR, Mannan RH, Wiebe LI, Chapman JD (1993) Imaging tumor hypoxia and tumor perfusion. J Nucl Med 34(6): 885-888.
17. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2(1): 38-47.
18. Harrison L, Blackwell K (2004) Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9(Suppl 5): 31-40.
19. Hayes AJ, Mostyn-Jones A, Koban MU, A'Hern R, Burton P, Thomas JM (2004) Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg 91(2): 242-247.
20. Ikeda E, Achen MG, Breier G, RisauW(1995) Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270(34): 19761-19766.
21. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706): 58-62.
22. Kao J, Chen C-T, Tong CL, Packer S, Schwartz M, Chen S-h Sung M (2014) Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases. Target Oncol 9(2): 145-153.
23. Lewin J, Puri A, Quek R, Ngan R, Alcasabas AP, Wood D, Thomas D (2013) Management of sarcoma in the Asia-Pacific region: resource-stratified guidelines. Lancet Oncol 14(12): e562-e570.
24. Linder C, Linder S, Munck-Wikland E, Strander H (1998) Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 18(3B): 2063-2068.
25. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med 356(2): 115-124.
26. Ngan SY (1997) Radiotherapy in soft tissue sarcoma of the extremities. Acta Orthop Scand Suppl 273: 112-116.
27. Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L (2004) The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7(3): 225-233.
28. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR, Danish H. Neck Cancer Study G (2005) Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6(10): 757-764.
29. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3): 220-231.
30. Pakos EE, Goussia AC, Tsekeris PG, Papachristou DJ, Stefanou D, Agnantis NJ (2005) Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res 25(5): 3591-3596.
31. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, Wester HJ, Beck R, McEwan AJ, Wiebe LI, Schwaiger M (2005) Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 46(1): 106-113.
32. Rajendra R, Jones RL, Pollack SM (2013) Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib. Onco Targets Ther 6: 217-222.
33. Rajendran J, Wilson D, Conrad E, Peterson L, Bruckner J, Rasey J, Chin L, Hofstrand P, Grierson J, Eary J (2003) [18 F] FMISO and [18 F] FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 30(5): 695-704.
34. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J (2002) Cytokine serum levels in soft tissue sarcoma patients: correlations with clinicopathological features and prognosis. Int J Cancer 100(4): 463-471.
35. Shah RR, Morganroth J, Shah DR (2013) Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 36(7): 491-503.
36. Shintani K, Matsumine A, Kusuzaki K, Matsubara T, Satonaka H, Wakabayashi T, Hoki Y, Uchida A (2006) Expression of hypoxia-inducible factor (HIF)-1a as a biomarker of outcome in soft-tissue sarcomas. Virchows Arch 449(6): 673-681.
37. Siemann DW, Johansen IM, Horsman MR (1998) Radiobiological hypoxia in the KHT sarcoma: predictions using the Eppendorf histograph. Int J Radiat Oncol Biol Phys 40(5): 1171-1176.
38. Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A, Dannenberg C, Tannapfel A, Kluge R, Sabri O (2003) [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 30(3): 317-326.
39. Spiro IJ, Gebhardt MC, Jennings LC, Mankin HJ, Harmon DC, Suit HD (1997) Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery. Semin Oncol 24(5): 540-546.
40. Stacker SA, Williams RA, Achen MG (2004) Lymphangiogenic growth factors as markers of tumor metastasis. APMIS 112(7-8): 539-549.
41. Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG (2014) Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer 14(3): 159-172.
42. van der Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379(9829): 1879-1886.
43. Vaupel P (2004) The role of hypoxia-induced factors in tumor progression. Oncologist 9(Suppl 5): 10-17.
44. Vaupel P, Harrison L (2004) Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9(Suppl 5): 4-9.
45. Wachsberger P, Burd R, Dicker AP (2003) Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9(6): 1957-1971.
46. Wang TB, Chen ZG, Wei XQ, Wei B, Dong WG (2011) Serum vascular endothelial growth factor-C and lymphoangiogenesis are associated with the lymph node metastasis and prognosis of patients with colorectal cancer. ANZ J Surg 81(10): 694-699.
47. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, DeLaney T, Glatstein E, Steinberg SM, Merino MJ, Rosenberg SA (1998) Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16(1): 197-203.
48. Yoon SS, Duda DG, Karl DL, Kim TM, Kambadakone AR, Chen YL, Rothrock C, Rosenberg AE, Nielsen GP, Kirsch DG, Choy E, Harmon DC, Hornicek FJ, Dreyfuss J, Ancukiewicz M, Sahani DV, Park PJ, Jain RK, Delaney TF (2011) Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys 81(4): 1081-1090.
49. Yoon SS, Segal NH, Olshen AB, Brennan MF, Singer S (2004) Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol 15(8): 1261-1266.
50. Yoon SS, Segal NH, Park PJ, Detwiller KY, Fernando NT, Ryeom SW, Brennan MF, Singer S (2006) Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res 135(2): 282-290.